BioProtect and the EIC Accelerator: Sold to Olympus for $270M

BioProtect, an Israeli company established in 2004, makes a biodegradable balloon that is implanted between the prostate and the rectum before radiotherapy for prostate cancer, pushing the bowel about 1.8 cm away from the radiation so it is not damaged. It was selected in the EIC Accelerator's March 2023 cut-off with blended finance and received an EU grant of €2.50 million for ProSpace, a €5.50 million project that ran from October 2023 to September 2025, according to CORDIS. The project was to bring manufacturing up to ISO 13485 standard, run a 100-patient study with commercial-scale devices, and collect data for FDA and EU MDR submissions.

The final report says all three were done: a new clean room in Netanya, a robotic balloon-folding machine and a new dipping system, 200 device sets produced for trials, 100 patients recruited at five centres in Poland, Israel, the Netherlands and Ireland, and "the new European certification from MDR", according to the CORDIS reporting page. On 26 May 2026 Olympus agreed to acquire BioProtect for $270 million, with part held in escrow, according to Olympus. The BioProtect website now says the company "is now part of Olympus".

Where BioProtect Stands Now

BioProtect is being absorbed into Olympus's Surgical and Interventional Solutions division. Olympus said the Balloon Spacer had been used in "more than 11,000 procedures worldwide" since its commercial introduction in 2023 and put BioProtect's workforce at 130. The original deal release gave 2025 revenue of about $14.5 million, according to LevinPro. The upfront part of the price and the escrow terms were not disclosed. Olympus lists its manufacturing site as Israel.

The Technology: A Dissolving Shield for the Bowel

Up to 35% of men treated with radiotherapy for prostate cancer suffer rectal side effects such as bleeding, the company says. Spacers push the rectum away from the high-dose area. Competitors such as SpaceOAR and BarriGel use injected gels; BioProtect uses a pre-formed saline-filled balloon inserted with blunt dissection rather than a needle, which it says gives a larger, symmetrical gap. The report claims a 63% cut in rectal radiation dose with no grade 3 adverse events, and safe use with short, high-dose courses of radiotherapy.

What the EIC Award Promised, and What the Record Shows

The award promised industrial manufacturing, a 100-patient study and regulatory data. All were reported done. One claim needs context: the report lists FDA "approval and certification" among project results, but the FDA cleared the device in August 2023, according to the FDA 510(k) database, before the project started in October 2023. The 100-patient study results have not been published in full.

1. ISO 13485 manufacturingDeliveredClean room, robotics.
2. 100-patient studyDeliveredFive centres, completed.
3. EU MDR certificationDeliveredPer final report.
4. Commercial scaleDelivered11,000+ procedures.

The Money

The EU paid 45% of the project. By the end of the project BioProtect employed 33 people in the US, where it launched in 2023, according to the final report. Whether the EIC Fund took shares under the blended finance award, and if so what it received from the Olympus deal, is not public.

What Cannot Be Checked

Why Europe Should Care

Prostate cancer is the second most common cancer in men, and many are treated with radiation. A spacer that protects the bowel improves quality of life. The EIC helped an Israeli company scale up a product that is now owned by a Japanese group; European patients gain from the MDR certificate, while the value created went to the company's owners.

The Verdict

BioProtect, Olympus and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.